Hematology & oncology

Click on each therapeutic area to learn more.

Myelofibrosis (MF)

MF is a rare hematologic cancer characterized by scarring of the bone marrow, as well as disruption of the normal production of blood cells. Approximately 20,000 people in the United States have been diagnosed with MF.

MF publications

The publications on this page are sponsored by Sobi and pertain to select Sobi products in this disease area. This page is not intended to serve as a comprehensive overview of all publications in this disease area. Publications may include information for which the product is not approved and/or that is inconsistent with the product uses described in the Prescribing Information. Sobi does not suggest or recommend the use of Sobi products in any manner other than as described in the Prescribing Information.

Improvement in Serum Albumin as a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: a Retrospective Analysis of Patients Treated Across Three Clinical Trials
Blood, November 2024
A Retrospective Analysis of Pacritinib Treatment Outcomes in Myelofibrosis Patients With and Without Monocytosis: A Randomized Clinical Trial
EHA2024 Hybrid Congress, June 2024
Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia
Journal of Clinical Oncology, May 2024
Impact of Pacritinib on Symptoms in Patients With Thrombocytopenia and Myelofibrosis Who Require Red Blood Cell Transfusion
Journal of Clinical Oncology, May 2024
Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States
Journal of Clinical Oncology, May 2024

Immune thrombocytopenia (ITP)

Immune thrombocytopenia (ITP) is a rare autoimmune disease affecting platelet production and characterized by bleeding, bruising, and fatigue. In the United States, approximately 9 to 10 people in every 100,000 have ITP.

ITP publications

The publications on this page are sponsored by Sobi and pertain to select Sobi products in this disease area. This page is not intended to serve as a comprehensive overview of all publications in this disease area. Publications may include information for which the product is not approved and/or that is inconsistent with the product uses described in the Prescribing Information. Sobi does not suggest or recommend the use of Sobi products in any manner other than as described in the Prescribing Information.

Safety, Efficacy, and Treatment Satisfaction in Adults With ITP Who Switched to Avatrombopag From Another TPO-RA
Blood, March 2025
Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects After Switching to Avatrombopag (AVA) From Eltrombopag (ELT) or Romiplostim (ROMI)
Blood, November 2024
Analysis of Durability of Response to Avatrombopag (AVA) From a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Patients With ITP
Blood, November 2024
Real-World Treatment Patterns and Outcomes in Patients With Immune Thrombocytopenia Treated With Avatrombopag in the United States: Real-AVA 2.0 Study Design
Blood, November 2023